Scientists test if lower dose of cancer drug works as well with fewer side effects
NCT ID NCT07092514
Summary
This study is for people with advanced thyroid cancer that has stopped responding to standard radioactive iodine treatment. Researchers want to see if a lower daily dose of the drug lenvatinib (10 mg) works as well as the standard higher dose (24 mg) while causing fewer side effects. They will compare how long the cancer stays under control and how often patients need to reduce or stop the drug due to side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.